Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

Summary by Hastings Tribune
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking…

1 Articles

Hastings TribuneHastings Tribune
Center

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking…

·Nebraska, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in Nebraska, United States on Tuesday, April 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Melbourne, Australia icon

Melbourne, Australia

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal